Targeting CDCP1 boost CD8+ T cells-mediated cytotoxicity in cervical cancer via the JAK/STAT signaling pathwayHua Huang, Yuwen Pan, Qiuwen Mai, Chunyu Zhang, Qiqiao Du, Yuandong Liao, Shuhang Qin, Yili Chen, Jiaming Huang, Jie Li, Tianyu Liu, Qiaojian Zou, Yijia Zhou, Li Yuan, Wei WangSee the full list of authors
24 October 2024
VHL missense mutation delineate aggressive clear cell renal cell carcinoma subtype with favorable immunotherapeutic responseZiyang Xu, Li Liu, Wenbin Jiang, Youqi Qiu, Boyu Zhang, Jiangting Cheng, Jiyan Luo, Jianming Guo, Jiejie Xu
23 October 2024
Alum-anchored IL-12 combined with cytotoxic chemotherapy and immune checkpoint blockade enhanced antitumor immune responses in head and neck cancer modelsKellsye P Fabian, Ginette Santiago-Sanchez, Michelle R Padget, Wiem Lassoued, Clint Tanner Allen, Sailaja Battula, Howard Kaufman, James W Hodge
23 October 2024
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancerNicolas Zhou, Cheuk H Leung, William N William, Jr, Annikka Weissferdt, Apar Pataer, Myrna C B Godoy, Brett W Carter, Frank V Fossella, Anne S Tsao, George R Blumenschein, Xiuning Le, Jianjun Zhang, Ferdinandos Skoulidis, Jonathan M KurieSee the full list of authors
23 October 2024
Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancerMarta Molina-Alejandre, Francisco Perea, Virginia Calvo, Cristina Martinez-Toledo, Ernest Nadal, Belén Sierra-Rodero, Marta Casarrubios, Joaquín Casal-Rubio, Alex Martinez-Martí, Amelia Insa, Bartomeu Massuti, Santiago Viteri, Isidoro Barneto Aranda, Delvys Rodriguez-Abreu, Javier de CastroSee the full list of authors
20 October 2024
First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironmentsAung Naing, Danny Khalil, Oliver Rosen, D Ross Camidge, Tom Lillie, Rui-Ru Ji, Andrea Stacey, Matthew Thomas, Lee Rosen
15 October 2024
SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137Takayuki Kamikawa, Naoki Kimura, Shinya Ishii, Masaru Muraoka, Tatsushi Kodama, Kenji Taniguchi, Moe Yoshimoto, Momoko Miura-Okuda, Ryo Uchikawa, Chie Kato, Junko Shinozuka, Sho Akai, Sotaro Naoi, Nanami Tomioka, Nishiki NagayaSee the full list of authors
14 October 2024
Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignanciesJoe Y Chang, Xinyan Xu, Girish S Shroff, Nathan I Comeaux, Wei Li, Jordi Rodon Ahnert, Daniel D Karp, Ecaterina E Dumbrava, Vivek Verma, Aileen Chen, James Welsh, David S Hong
9 October 2024
Dendritic cells pulsed with multifunctional Wilms’ tumor 1 (WT1) peptides combined with multiagent chemotherapy modulate the tumor microenvironment and enable conversion surgery in pancreatic cancerShigeo Koido, Junichi Taguchi, Masamori Shimabuku, Shin Kan, Tuuse Bito, Takeyuki Misawa, Zensho Ito, Kan Uchiyama, Masayuki Saruta, Shintaro Tsukinaga, Machi Suka, Hiroyuki Yanagisawa, Nobuhiro Sato, Toshifumi Ohkusa, Shigetaka ShimodairaSee the full list of authors
8 October 2024
Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trialBixia Tang, Yu Chen, Yu Jiang, Meiyu Fang, Quanli Gao, Xiubao Ren, Li Yao, Gang Huang, Jing Chen, Xiaoshi Zhang, Rongqing Li, Shuai Zhao, Meijuan Gao, Ruixuan Luo, Meng QiSee the full list of authors
4 October 2024